Navigation Links
Poniard Pharmaceuticals Provides Year-End Clinical Update at 2007 Lazard Capital Markets Healthcare Conference
Date:11/27/2007

- Significant clinical progress noted in small cell lung, prostate and

colorectal cancer trials -

SOUTH SAN FRANCISCO, Calif., Nov. 27 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused on oncology, today provided an update of its picoplatin development program in small cell lung cancer (SCLC), colorectal cancer (CRC) and hormone refractory prostate cancer (HRPC), and its oral formulation in solid tumors. Presenting at the Lazard Capital Markets Healthcare Conference in New York, Jerry McMahon, Ph.D., chairman and CEO of Poniard, noted that the Company has made significant progress in 2007 in its clinical development program for picoplatin, its lead product candidate.

"2007 has been an important year for Poniard, as we have continued to advance our development of picoplatin, a new generation chemotherapy agent with the potential to become a platform product addressing multiple indications, combinations and formulations," said Dr. McMahon. "We continue to drive our clinical programs toward completion and have achieved significant milestones this year. In addition, we remain on track to file our NDA for picoplatin in 2009."

Poniard is providing an update on the progress on all four of its picoplatin clinical trials, as follows:

Phase 3 SPEAR Trial:

Poniard is evaluating intravenous picoplatin in an ongoing pivotal Phase 3 trial, known as SPEAR (Study of Picoplatin Efficacy After Relapse), in SCLC. This registrational trial is being conducted under a Special Protocol Assessment (SPA) from the U.S. Food and Drug Administration (FDA) and is evaluating overall survival as the primary endpoint.

To date
'/>"/>

SOURCE Poniard Pharmaceuticals
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Poniard Pharmaceuticals to Present Updated Results of Picoplatin Phase 2 Small Cell Lung Cancer Trial at 12th World Conference on Lung Cancer
2. Poniard Pharmaceuticals Announces Updated Results of Picoplatin Phase 2 Trial Demonstrating Survival Benefit in Small Cell Lung Cancer Patients
3. Poniard Pharmaceuticals Receives FDA Fast Track Designation for Picoplatin for Treatment of Small Cell Lung Cancer
4. Poniard Pharmaceuticals Initiates Randomized Phase 2 Trial of Picoplatin for First-Line Treatment of Metastatic Colorectal Cancer
5. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
6. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
7. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
8. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
9. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
10. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
11. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... R.I. , July 10, 2014 CVS Caremark ... board of directors has approved a quarterly dividend of $0.275 ... dividend is payable on August 1, 2014, to holders of ... CVS Caremark is dedicated to helping people ... pharmacy company in the United States . ...
(Date:1/15/2014)... 15, 2014 Sono-Tek Corporation (OTC BB: SOTK) today announced ... 2013, compared to sales of $2,202,000 for the prior year ... quarter has also shown growth over the preceding quarter,s sales, ... this fiscal year. Markets that experienced sales increases over the ...
(Date:1/15/2014)... Most osteoporosis patients want a choice in the medication ... by Mission Pharmacal Company. The survey, conducted by ... community, revealed that 74 percent of osteoporosis patients surveyed ... other than a pill or a tablet. ...
Breaking Medicine Technology:Sono-Tek Announces Third Quarter Results 2Sono-Tek Announces Third Quarter Results 3Sono-Tek Announces Third Quarter Results 4Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 2Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 3
... UPPSALA, Sweden, April 14 Oasmia,Pharmaceutical, Uppsala, Sweden, ... FDA of Paclical(R) for the treatment of ovarian ... FDA to expedite and,optimize drug development and upon ... (Logo: http://www.newscom.com/cgi-bin/prnh/20070918/273312 ...
... Entry into Oncology Market; Rosetta to Receive Milestones ... DIEGO, PHILADELPHIA and REHOVOT, Israel, April 13 ... company, and Rosetta Genomics Ltd. (Nasdaq: ... announced the execution of a license and collaboration ...
Cached Medicine Technology:Oasmia: FDA Grants Paclical(R) Orphan Drug Designation for Ovarian Cancer in the USA 2Prometheus and Rosetta Genomics Announce License and Collaboration Agreement 2Prometheus and Rosetta Genomics Announce License and Collaboration Agreement 3Prometheus and Rosetta Genomics Announce License and Collaboration Agreement 4Prometheus and Rosetta Genomics Announce License and Collaboration Agreement 5Prometheus and Rosetta Genomics Announce License and Collaboration Agreement 6
(Date:7/11/2014)... London, UK (PRWEB) July 11, 2014 ... segment of the in-vitro diagnostics industry, which is expected ... next ten years. The sector owes its growth to ... threat to people’s health worldwide and a major factor ... diagnostic technologies, threat of bio-terrorism, and a broader availability ...
(Date:7/11/2014)... 2014 The report, “Specialty Synthetic ... & Geography - 2018,” defines and segments the ... an analysis and forecast of the volumes and ... (Para aramids, meta aramids, UHMW Polyethylene, carbon fiber, ... fiber, PBI fiber, PBO fiber, and liquid crystal ...
(Date:7/11/2014)... (PRWEB) July 11, 2014 Datalogic brings ... in improving sanitation hospital wide. With their new ... spread of disease, like the devastating MRSA, which claimed ... Gryphon GD4400-HC 2D and the Gryphon GM4400-HC ... barcodes and can even read barcodes off of troublesome ...
(Date:7/11/2014)... 11, 2014 Operators and ... billion in fuel costs now that model ... current GHG standards are phasing in ... upon themselves to install new features into ... reduction technologies , 2.    Efficient driveline components which ...
(Date:7/11/2014)... -- Children who have emergency surgery on weekends ... even death than those who have weekday surgeries, ... Johns Hopkins researchers noted that the risk of ... on nearly 440,000 simple emergency surgeries that children ... period. The surgeries are considered generally safe ...
Breaking Medicine News(10 mins):Health News:World Virology and Bacteriology Testing Sector Discussed in Comprehensive VPG Research Report Published at MarketPublishers.com 2Health News:World Virology and Bacteriology Testing Sector Discussed in Comprehensive VPG Research Report Published at MarketPublishers.com 3Health News:Specialty Synthetic Fibers & Glass Fiber Market Poised to Reach $20.1 Billion at a CAGR of 5.2% by 2018 – Report by MarketsandMarkets 2Health News:Specialty Synthetic Fibers & Glass Fiber Market Poised to Reach $20.1 Billion at a CAGR of 5.2% by 2018 – Report by MarketsandMarkets 3Health News:Specialty Synthetic Fibers & Glass Fiber Market Poised to Reach $20.1 Billion at a CAGR of 5.2% by 2018 – Report by MarketsandMarkets 4Health News:Stop Spreading Disease with the New Disinfectant-Ready Bar Code Scanner 2Health News:Stop Spreading Disease with the New Disinfectant-Ready Bar Code Scanner 3Health News:LeaseQ Agrees the Latest Round of Greenhouse Gas Rules Could Increase the Cost of Truck Acquisition and Maintenance 2Health News:LeaseQ Agrees the Latest Round of Greenhouse Gas Rules Could Increase the Cost of Truck Acquisition and Maintenance 3Health News:Emergency Surgeries on Weekends Riskier for Kids: Study 2
... Job Creation and Employee Training, DURHAM, N.C., March ... one of the Triangle,s top employers for making the,community ... and Wake Tech Community College selected Parata for the ... the region,s,talent pool., Parata grew from a startup ...
... Issues Temporary Restraining Order, ALLEGAN, Mich., March 11 ... that it has received final approval,from the U.S. Food ... (ANDA) for Clobetasol Propionate Foam, 0.05%., The product ... to severe dermatosis of the scalp. Sales for the ...
... CEO and Founder of,Ingenious Med and a practicing ... serve on the Benchmarks Committee for the Society ... of the Benchmarks Committee,will make recommendations to the ... and review. This will include shaping processes for ...
... and Children,s Healthcare of Atlanta are teaming up with ... to make kidney transplants more tolerable for children. ... Childrens Hospital in Los Angeles and Lucile Packard Children,s ... of kidney transplants in children. , The National ...
... at Georgetown University, has been named a member of ... Crawford is in the Tumor Biology Program at ... University Medical Center. , The Bouchet Society is named ... United States (Physics, Yale University, 1876). The Society ...
... PHILADELPHIA World-class cancer researchers whose science has significantly ... be recognized April 12-16, 2008, by the American Association ... at the San Diego Convention Center in San Diego, ... annually by the AACR, the worlds oldest and largest ...
Cached Medicine News:Health News:Parata Systems Named '2008 Business Champion' 2Health News:Perrigo Company Receives Final Approval on Clobetasol Propionate Foam 2Health News:Perrigo Company Receives Final Approval on Clobetasol Propionate Foam 3Health News:Dr. Steve Liu, CEO of Ingenious Med, Joins Benchmarks Committee at SHM 2Health News:NIH grant to Emory and pediatric partners aims to improve kidney transplants for children 2Health News:Georgetown U student selected for prestigious Bouchet Society 2Health News:Leading researchers honored for progress in cancer prevention, detection and treatment 2Health News:Leading researchers honored for progress in cancer prevention, detection and treatment 3Health News:Leading researchers honored for progress in cancer prevention, detection and treatment 4Health News:Leading researchers honored for progress in cancer prevention, detection and treatment 5Health News:Leading researchers honored for progress in cancer prevention, detection and treatment 6Health News:Leading researchers honored for progress in cancer prevention, detection and treatment 7
Perforated or Rod Top, Free Standing or Wall Mounted, Storage Cubby Optional, Polypropylene Construction...
... metal frames ensure cleanroom ... cleanliness and chemical resistance. ... with user-friendly pnuematic controls ... Fixed footring standard. Five ...
... Cleanroom-grade vinyl curtains or parting ... steel support frame to form ... that meets cleanliness to Class ... filter/fan units, lights, and ionizers ...
Inquire...
Medicine Products: